Ratings CureVac N.V.

Equities

CVAC

NL0015436031

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
3.13 ^USD	+13.00%		+34.33%	-25.65%

May. 02	CUREVAC : A missed opportunity
Apr. 26	UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company is in a robust financial situation considering its net cash and margin position.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Revenue estimates are regularly revised downwards for the current and coming years.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CUREVAC N.V.	-25.65%	701M	D+
MODERNA, INC.	+25.69%	47.86B	B-
LONZA GROUP AG	+46.90%	41.42B	A
IQVIA HOLDINGS INC.	-3.46%	40.66B	B
CELLTRION, INC.	-6.20%	28.92B	C
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B	B
BIO-TECHNE CORPORATION	+0.17%	12.15B	B+
MEDPACE HOLDINGS, INC.	+28.07%	12.14B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes